Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rigosertib in Relapsed/Metastatic SCC
NCT01807546Phase 2Completed
- Sponsor
- Traws Pharma, Inc.
- Start
- Mar 2013
- Primary completion
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rigosertib in head and neck squamous cell carcinoma (HNSCC), anal squamous cell carcinoma (SCCA), squamous cell carcinoma of the lung (LSCC) and 4 more, sponsored by Traws Pharma, Inc. Primary endpoint: Overall Response Rate at 2 years. Started Mar 2013; status: completed.
02
Drugs
rigosertib
03
Conditions
head and neck squamous cell carcinoma (HNSCC)anal squamous cell carcinoma (SCCA)squamous cell carcinoma of the lung (LSCC)cervical squamous cell carcinoma (CSCC)Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT01807546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01807546.